Core Viewpoint - ImmuCell Corporation reported preliminary, unaudited sales results for Q4 and full year 2025, indicating a mixed performance with a slight decline in quarterly sales but an overall increase in annual sales [1][3]. Sales Performance - Total sales for Q4 2025 were $7.6 million, a 1.6% decline from $7.8 million in Q4 2024 [3]. - Total sales for the full year 2025 reached $27.6 million, representing a 4.3% increase compared to $26.5 million in 2024 [3]. - Domestic sales for Q4 2025 were $7.0 million, an 8.7% increase from $6.4 million in Q4 2024 [5]. - International sales for Q4 2025 were $0.6 million, a significant decline of 52.6% from $1.3 million in Q4 2024 [5]. Product Line Performance - Tri-Shield sales for Q4 2025 were $6.0 million, a 41.3% increase from $4.2 million in Q4 2024 [5]. - Dual-Force and other sales for Q4 2025 were $1.7 million, a 53.0% decline from $3.6 million in Q4 2024 [5]. - For the full year 2025, Tri-Shield sales totaled $19.9 million, a 26.5% increase from $15.8 million in 2024 [5]. - Dual-Force sales for the full year 2025 were $6.9 million, a 27.4% decline from $9.6 million in 2024 [5]. Strategic Focus - The company announced a strategic shift to focus on expanding the First Defense product line after receiving an FDA Incomplete Letter for the Re-Tain product [3][6]. - ImmuCell plans to repurpose assets related to Re-Tain, valued at approximately $15.5 million, to enhance the First Defense product line [3][4]. - Manufacturing improvements have increased output of the lyophilization process by over 15% year-over-year in 2025, with plans for similar enhancements in 2026 [4]. Financial Write-Downs - The company expects to record a non-cash impairment write-down of approximately $2.9 million related to Re-Tain during Q4 2025 [3][4]. - Additional write-downs include $0.1 million for other property, plant, and equipment, and $0.6 million for inventory deemed unfit for processing [4].